Policy TopicRegulatory
The Regulatory Performance Committee provides strategic advice and guidance on policy items affecting a high performing, world class regulatory system that is predictable, efficient, consistent and transparent, avoiding barriers to business investment which are key to cementing Canadians' access to biotechnology innovation. The Regulatory Performance Committee tackles critical issues from start-up to multi-national to ensure innovative life-saving biotech treatments are developed in Canada and are available to Canadian citizens by:
- Attracting global clinical trials and R&D operations
- Reducing time to market for new therapies, improving patient access
- Signalling to international commercial investors that Canada is innovation-ready
- Accelerating commercialization of homegrown biotech innovation
August 12, 2026
Statement from BIOTECanada on the Pharmaceutical and Life Sciences Sector Task Force Report to the Ministers of Health and Industry
On behalf of the biotech sector, BIOTECanada welcomes the report of the Pharmaceutical and Life Sciences Sector Task Force released today.
Read More
August 12, 2026
Biotechnology Ecosystem
The world’s population is predicted to grow to almost 10 billion people by 2050. This means drastic global changes in human health, the environment, food security and economic fortunes have already started to impact our day to day lives.
Read More
April 8, 2026
BIOTECanada responds to CDA-AMC Guidance for Incorporating Impacts on Informal Caregivers and Productivity Outcomes in Economic Evaluations.
BIOTECanada in collaboration with Innovative Medicines Canada responded to the Canadian Drug Agency’s consultation on its proposed Guidance for Incorporating Impacts on Informal Caregivers and Productivity Outcomes in Economic Evaluations. This reflects a positive step towards evolving HTA to better capture the full value of innovation by incorporating informal caregiver health-related quality of life, and patient and…
Read More
MembershipJoin the voice of Canadian biotech
- A seat at the table in federal policy consultations
- Members-only insights, briefings, and the CEO Report
- Cost savings program with vetted industry suppliers
- Discounted access to BIONATION and Canada @ BIO
230+
- Health & pharmaceutical
- Agricultural biotechnology
- Industrial & environmental
- Emerging fields